Aurobindo Pharma Ltd 2017 Annual Report with Sustainability Disclosures
Company: Aurobindo Pharma Ltd
Sector: Manufacturing
Country: India
Year: 2017
Type: Annual Report with Sustainability Disclosures
Pages: 228
The report presents Aurobindo's FY2016-17 consolidated revenue of ₹150,898.6 million. It highlights investments in energy efficiency, including a 30MW captive solar plant, alongside ISO 14001 accreditation and wastewater initiatives. CSR spending totaled ₹193,584,277, supporting education, healthcare, water, sanitation, rural sports and other community programs.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.